24115-89-7

Upstream product

• 533897-93-7 3-benzyloxy-2-nitrobenzoic acid methyl ester 
• 602-00-6 3-hydroxy-2-nitrobenzoic acid 
• 94863-06-6 benzyl 3-benzyloxy-2-nitrobenzoate 
• 89942-77-8 methyl 3-hydroxy-2-nitrobenzoate 
• 4920-77-8 3-methyl-2-nitrophenol 
• 4920-80-3 3-methoxy-2-nitrobenzoic acid 
• 5345-42-6 1-methoxy-3-methyl-2-nitro-benzene 
• 108-39-4 3-methyl-phenol 

Downstream Products

• 24115-90-0 2-nitro-3-benzyloxybenzoyl chloride 
• 5183-97-1 (2S,3R)-2-(3-Benzyloxy-2-nitro-benzoylamino)-3-hydroxy-butyric acid 
• 61535-24-8 2-amino-3-(benzyloxy)benzoic acid 
• 177477-63-3 tert-butyl 3-(benzyloxy)-2-nitrophenylcarbamate 
• 33145-22-1 5-nitro-3-benzyloxy benzoyl chloride 
• 432029-31-7 4'-chloro-2'-[(5-chloro-2-pyridyl)carbamoyl]-6'-hydroxyl-1-isopropylpiperidine-4-carboxanilide hydrochloride 
• 432029-33-9 4'-bromo-2'-[(5-chloro-2-pyridyl)carbamoyl]-6'-hydroxyl-1-isopropylpiperidine-4-carboxanilide hydrochloride 
• 432029-32-8 4'-chloro-2'-[(5-chloro-2-pyridyl)carbamoyl]-6'-hydroxyl-1-isopropylpiperidine-4-carboxanilide 

Relevant academic research and scientific papers

A chiral oxazoline for catalytic enantioselective Nozaki-Hiyama-Kishi allylation and vinylation of aldehydes

Asymmetric allylation and vinylation of aldehydes with allyl halides and vinyl halides have been achieved using the chromium(II)-oxazoline catalyst. The catalyst promotes the highly efficient enantioselective Nozaki–Hiyama-Kishi (NHK) allylation of aldehydes using allyl bromide, producing the corresponding homoallylic alcohols in good yields (up to 84%) and a high level of enantioselectivity (up to 98% ee). Meanwhile, the NHK vinylation of aldehydes produce desired allylic alcohols in satisfactory yields (up to 88%) and a high level of enantioselectivity (up to 97% ee). We developed a reliable and milder protocol for preparing chiral homoallylic and allylic alcohols.

In pursuit of natural product leads: Synthesis and biological evaluation of 2-[3-hydroxy-2-[(3-hydroxypyridine-2-carbonyl)amino]phenyl]benzoxazole-4- carboxylic acid (A-33853) and its analogues: Discovery of N-(2-benzoxazol-2- ylphenyl)benzamides as novel

The first synthesis and biological evaluation of antibiotic 31 (A-33853) and its analogues are reported. Initial screening for inhibition of L. donovani, T. b. rhodesiense, T. cruzi, and P. falciparum cultures followed by determination of IC50

Diazepane derivatives or salts thereof

To provide a compound which has an anticoagulation action based upon inhibition of activated blood coagulation factor X and is useful as an anticoagulant or an agent for prevention and treatment of diseases caused by thrombus or embolus. A diazepan deriva

SUBSTITUTED BENZENE DERIVATIVES OR SALTS THEREOF

There are provided compounds having an anticoagulant action on the basis of inhibition of activated blood coagulation factor X and being useful as anticoagulants or preventive/therapeutic agents for diseases induced by thrombosis or embolism. Effective ingredients are the compounds such as 4'-bromo-2'-[(5-chloro-2-pyridyl)carbamoyl)-6-β-D-galactopyranosyloxy-1-isopropylpiperidine-4-carboxanilide, 2'-(2-acetamido-2-deoxy-β-D-glucopyranosyloxy)-4'-bromo-6'-[(5-chloro-2-pyridyl)carbamoyl]-1-isopropylpiperidine-4-carboxanilide, etc. or salts thereof.

Benzimidazole compounds as bradykinin antagonists

PCT No. PCT/JP95/01478 Sec. 371 Date Feb. 3, 1997 Sec. 102(e) Date Feb. 3, 1997 PCT Filed Jul. 25, 1995 PCT Pub. No. WO96/04251 PCT Pub. Date Feb. 15, 1996This invention relates to a heterocyclic compound of the formula: wherein a group of the formula: is a group of the formula: etc., X is O, S or N-R5, R1 is lower alkyl, etc., R5 is hydrogen, lower alkyl, etc., R2 is hydrogen, halogen, lower alkyl, etc., R3 is halogen, lower alkyl, etc., R4 is amino optionally having suitable substituent(s), and A is lower alkylene, and a salt thereof, to processes for preparation thereof, and to a pharmaceutical composition comprising the same for the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a]pyridine moiety

Recently we reported on overcoming the species difference of our first orally active non-peptide bradykinin (BK) B2 receptor antagonists, incorporating an 8-[[3-(N-acylglycyl-N-methylamino)-2,6-dichlorobenzyl]oxy]- 3-halo-2-methylimidazo[1,2-α]

Heterocyclic amido derivatives of substituted benzoic acids and therapeutic compositions which contain them as active principle

Heterocyclic amido derivatives of substituted benzoic acids of general formula (I): in which:, R1 is H; 3-OCH3; 3-Cl; 4-Cl; 5-Cl; 3-CH3; 5-CH3; or 3-OH; -CH2-COOH; or -CH2-CO2-C